TrialBMJ open2022

Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.

Frederik Husum Mårup et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.